NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating RRMM
MYELOMA CLINICAL TRIALS - PHASE 2




- Jun 10, 2022
NCT05177536: Phase 2: Iberdomide Maintenance Therapy in Patients With Multiple Myeloma


- Jun 10, 2022
NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for Myeloma in Patients Progressing on CAR-T


- May 30, 2022
NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma - iMMagine-1


- May 25, 2022
NCT05393804: Phase 2: Trial of CART Ide-cel (bb2121) Status Post Hematopoietic cell Transplantation


- Apr 28, 2022
NCT05354557: Phase 2 - Study of Iberdomide in Multiple Myeloma Post ASCT Transplant


- Apr 25, 2022
NCT05346809: Phase 2: Isatuximab During Stem Cell Collection and Transplant in Myeloma & Lymphoma


- Apr 25, 2022
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release


- Apr 19, 2022
NCT05338047: Phase 2: Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery ASCT


- Apr 19, 2022
NCT05336383: Phase 2: Phase II Study of Salvage Radiation Treatment After BCMA CART Therapy for RRMM


- Apr 6, 2022
NCT05317416: Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7


- Mar 17, 2022
NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex


- Mar 9, 2022
NCT05272826: Phase 2: Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients


- Mar 1, 2022
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)


- Dec 29, 2021
NCT05172596: Phase 2: PHE885 CAR-T Therapy in Adult Participants With Relapsed Refractory Myeloma


- Dec 17, 2021
NCT05064358: Phase 2 - Alternative Dosing Regimens of Belantamab Mafodotin RRMM - (DREAMM 14)


- Dec 16, 2021
NCT05130827: Phase 2: Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing ASCT


- Dec 16, 2021
NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902


- Dec 1, 2021
NCT05123131: Phase 2: Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma (Isa-RVD)


- Aug 19, 2021
NCT05014646: Phase 2: Leflunomide for High-Risk Smoldering MM in African-Am. & European-Am. Patients


- Aug 9, 2021
NCT04998786: Phase 2: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide & Dex RRMM


- Aug 6, 2021
NCT04816526: Phase 2 - Descartes-08 anti-BCMA-CAR-mRNA-transf. auto CD8+ T cells Consolidation MRD+


- Jun 25, 2021
NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)


- Jun 24, 2021
NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST)


- Jun 23, 2021
NCT04843579: Phase 2: Selinexor in Combination With Clarithromycin, Pom & Dex RRMM - ClaSPd


- Jun 23, 2021
NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma


- Jun 10, 2021
NCT04891809: Phase 2 - Isatuximab in Combination With Rd Compared to Rd in Elderly NDMM


- Jun 10, 2021
NCT04835129: Phase 2: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in RRMM (IMPEDE)


- Jun 9, 2021
NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction & Lenalidomide Maint


- Jun 9, 2021
NCT04776395: Phase 2: Iberdomide Alone or in Combination With Dex for Intermediate/High-Risk SMM


- Jun 9, 2021
NCT04717700: Phase 2: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dex in TIE NDMM


- Jun 8, 2021
NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor MM


- Jun 8, 2021
NCT04892446: Phase 2: Study of Magrolimab Combinations in Participants With Relapsed/Refractory MM


- May 31, 2021
NCT04814615: Phase 2: A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma


- Dec 23, 2020
NCT04680468: Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant & Maintenance


- Dec 17, 2020
NCT04497961: Phase 2: A Study of Health-Related Quality of Life with Daratumumab or Lenalidomide


- Dec 11, 2020
NCT04508790: Phase 2: Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of RRMM Myeloma


- Dec 10, 2020
NCT04268199: Phase 2: Exploring Self-Administration of Chemo in the Home Environment (EASE)


- Dec 10, 2020
NCT04287855: Phase 2: Phase 2 Study of Isatuximab + Pomalidomide, Dex, Carfilzomib RRMM -IFM2018-03


- Dec 10, 2020
NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)


- Dec 9, 2020
NCT04564703: EMN26 Phase 2: Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients


- Dec 9, 2020
NCT04617925: Phase 2: EMN 27 - Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis


- Dec 8, 2020
NCT04258683: Phase 2: Pembrolizumab Added to the Standard First-Line therapy (CyBorD) for NDMM NTE


- Dec 4, 2020
NCT04653246: Phase 2: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM


- Dec 3, 2020
NCT04552743: Phase 2: MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for ASCT


- Dec 2, 2020
NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma


- Dec 2, 2020
NCT04436029: Phase 2: Descartes-11 Consolidation Treatment Patients With High-Risk Multiple Myeloma


- Jul 17, 2020
NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)